1. Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review. (3rd October 2022) Authors: Frantz, R P; Shlobin, O A; Raina, A; Wu, B; Broderick, M; Classi, P; Sketch, M R Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗